Intensive monitoring for adverse drug effects in patients discharged from acute medical wards.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D004487:Edema / Q000139:chemically induced; D005006:Ethnicity; D005260:Female; D005905:Glyburide / Q000009:adverse effects; D006035:Glycyrrhiza; D006402:Hematologic Diseases / Q000139:chemically induced; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D010044:Outpatient Clinics, Hospital; D010634:Phenobarbital / Q000009:adverse effects; D010946:Plants, Medicinal; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D011802:Quinidine / Q000009:adverse effects; D012737:Sex Factors; D013386:Succinates / Q000009:adverse effects; D014315:Triterpenes / Q000009:adverse effects; D014859:Warfarin / Q000009:adverse effects
D013386:Succinates; D014315:Triterpenes; D014859:Warfarin; D011802:Quinidine; D005905:Glyburide; D010634:Phenobarbital